Prenetics Global Limited (PRE) Earnings Call Transcript
November 18, 2026
Earnings Call Speaker Segments
Appreciate that, Shannon. Morning, everyone, and thank you for joining us. I'm Danny Yeung, Co-Founder and CEO of Prenetics. Our CFO designate, Brian Rosin, is here too; Brian will take over the CFO role from Steven Lowe on December 31. Since joining IM8 in May, he's helped secure our $1 billion growth financing commitment from General Catalysts, strengthened our finance leadership team in the U.S., met hundreds of investors, and engaged with numerous new research analysts. I'd also like to thank Steven for his 8 years at Prenetics. Stephen, thank you for your dedication and partnership. Happy to have you remaining on board as a senior adviser; with that said, let's begin, everybody. Once more, thanks for being here. Turning now to this quarter. Please turn to Slide 4. I'll begin with the commitment we gave three months ago. We told you adjusted free cash flow was going to become positive during Q3. That is what happened, at $4.1 million, with $27.5 million of cash used in operations, which was more than offset by $31.6 million of net funding from General Catalyst; we also said revenue would land between $63 million and $64 million, and we came in right at the top of that range. As of today, we are reaffirming 2 numbers. For the full year '26, we're looking at revenue between $220 million and $230 million, and I mentioned revenue north of $400 million for the following year. There's one figure we discussed back in August that we've decided to shift. Our expectation now is a second half adjusted EBITDA loss ranging from $30 million to $35 million, compared with the $8 million to $12 million we had guided to earlier. We understand this represents a substantial charge — a substantial change — and it's a deliberate decision on our part, reflecting the returns we're seeing. Our cash position is growing thanks to the General Catalyst financing, 70% of our marketing, new products in the pipeline, and how early we still are in this category. We're putting more money in, and in a few minutes I'll explain the reasoning. As noted earlier, revenue came in at $64.1 million in total, with IM8 adding $62.9 million, which is up nearly 40% versus Q2. We achieved that even as our customer acquisition cost declined for a second straight quarter. IM8 revenue has now risen across 6 quarters in a row. Our best month ever was September, at $23.7 million of revenue, which works out to an annualized revenue run rate of $284 million. Moving to the next slide. Those are the headline results. What matters more is what sits underneath them, and there's a single number I'll keep returning to. To date, across the first six quarters of this year, each dollar spent on customer acquisition has generated $1.68 in return. That figure represents gross profit—the amount remaining after manufacturing and shipping the product. It's calculated the same way General Catalyst did, using a margin more conservative than what we actually achieve. Also, remember that when General Catalyst made that commitment in July, the figure stood at about $1.44, so it keeps compounding month over month. This key metric also prompts the question: where will that number ultimately land, and how will it shift over time? Our earliest customers are now showing us the answer. Moving to the next slide, what you're looking at is actually our earliest cohorts. Once more, this is a major reason we're directing additional investment into the business, since you can see here that in our first full quarter of operations—Q1 of 2005—we brought in 27,000 customers during that year. Today, that same cohort has delivered $4.10 in gross profit for each dollar we spent acquiring them, and we achieved this in less than two years. A lot of you are aware that within the DDC subscription base, one key metric serves as the gold standard — if we can reach it, the business will be solid. That metric is a 3:1 LTV-to-CAC ratio measured on gross profit. We've managed to achieve that with our first cohorts. And as you can see with the next two cohorts — 91,000 customers acquired in Q2 and Q3 of last year — the figure stands at roughly 2.7:1 right now; and at the current pace, we expect to reach that target in early 2027. There's one point worth noting, however: acquiring those earlier customers set us back roughly $104 apiece, compared with $285 at present. Yet buyers today spend considerably more on an initial order — around $207 as opposed to $113 — and they return our acquisition cost in roughly six months. Our threshold for these cohorts remains unchanged at 3:1. Usually, that 3:1 benchmark is reached in about 36 months. We've now demonstrated it across approximately dry cohorts, and we'll achieve it in roughly under two years. Moving to the next slide; keeping those trends in view, I'll now address the question. I imagine a lot of you are wondering, for Brian and me: we hit the revenue guidance. So why is the loss bigger than the range we provided back in August? As we noted, we now anticipate a second-half adjusted EBITDA loss of roughly $30 million to $35 million. Back in August, the figure we gave was $8 million to $12 million. At this point, given the weight of the evidence in front of us, we're deliberately putting money into growth—and each quarter adds further proof of that. I'll lay this out for you across five separate parts. Starting with the first part, as you just saw, again, more than 4 for our earliest customers, close to 3 for the next 91,000, and roughly 6 months to recover what a customer costs us today. The second reason: this past quarter we spent a record amount and brought in the largest group of new customers we've ever had. In September alone, we brought on over 52,000 new customers, and 4 in 10 of those paid for 3 months upfront. September was where we pushed hardest, and that meant our cost per customer was higher than it was in July. Despite that, our average cost to acquire a customer fell again this quarter — the second consecutive decline — coming in at about $285, right? Reason three: we posted 38% growth this quarter, and cash also increased, so we ended September with $111.5 million in cash and investments, compared with $109.4 million in June, across a quarter of record spending. The explanation is that we just completed the first full quarter under the $1 billion commitment from General Catalyst, and it performed exactly as intended. They covered 70% of our customer acquisition spending, and they get repaid by capturing a portion of the revenue those same customers generate. That frees up our capital for new products, 3 clinical trials, substantial brand marketing, and whatever is coming in '27. So each return I displayed a moment ago was generated solely by our core products, which is essentially 2 products. Hydration launches in the first quarter of next year. And since August, we have signed care bears by IM8.
Each customer we add today is one we can support financially — someone to whom we can sell a second and third product without spending anything more on acquisition. And fifth, the opportunity. It seems almost unbelievable that despite tremendous growth over the last 22 months, we still have just a 0.14% share of a $200 billion category, which honestly has no dominant leader; that said, this isn't an unlimited pledge to keep spending. We'll continue investing at this rate as long as those returns remain solid. Two figures govern this and how we assess it each quarter: what it costs to acquire a customer, and the gross profit each cohort of those customers gives back to us. If either one were to turn against us, we would pull back, and you would hear about it from us. You would hear it from us first. But when you put those 5 together, investing less would truly be the costly error. And we are doing this from a position of strength. The business we have already built generated $30.6 million this past quarter before acquisition marketing and brand partner costs. If we halted new customer acquisition tomorrow, the customers we have today, we are ready to make the company profitable on an adjusted EBITDA basis. So everything I have shown you so far comes from our own data. As we demonstrated in the prior quarter, we obtained third-party card data from Integari, so there's no need to simply trust our own figures. We can now evaluate this using an independent perspective. Bear in mind that what we're looking at is U.S. card activity we've observed, covering only part of our own store, not the revenue we report. I'll begin with retention, since within a subscription operation, scale is paramount. We've operated in this space for just 22 months now, yet after that period, 11% of IM8 customers continue to purchase from us. By comparison, Dawn stands at 8.7%, AT1 at 8.5%, and Kruse at 7.4%. This panel also illustrates our pace of growth. Moving to the next slide. During the first nine months of 2026, IM8 sales within the panel rose 348% compared with the prior year. Meanwhile, our share across these 4 brands climbed from 1% last January to 16% in December; the complete investor deck, along with the slides, is available in the shareholder letter for anyone to review. We observe that same loyalty in the SA business. Roughly 59% of customer buildings this quarter originated from repeat orders. Quarterly plans accounted for about 61% of September billings, and we closed September with approximately 160,000 active subscriptions; so what we're saying is that a customer stay. Our retention cohort ranks among the strongest in the category, and the question is how we keep bringing in new ones. Moving to the next slide. Our partners provide much of that answer. David Beckham co-founded IM8, as everyone is aware. The group standing with us includes Giannis, Aryna Sabalenka, Ollie Bearman, Jay Shetty, Lilly Collins, Inter Miami, and, joining just this week, Diplo. Six of those individuals signed on only this year. Every single one of them owns stock in Prenetics, because what we're looking for is partners who truly care about what this company becomes over the years. And another interesting thing is that every one of these individuals came to us on their own initiative, which is a powerful indication that they've tried the product and really put it through its paces. Then in October—just last month—we went a step further and became the NBA's official nutrition partner across Australia and 8 Southeast Asian markets, which together cover 660 million people. That's also the first time the NBA has ever partnered with a supplement brand on a worldwide basis. Let's move to the next slide. Before we move on, I want to touch on something — again, partners open the door, but the product must earn its place, and that's where the science comes in too. We already have one completed randomized controlled trial supporting our flagship. We also currently have 3 additional randomized placebo-controlled trials in progress. Two are in longevity — no result yet, and we'll publish whatever we find. And naturally, that's the evidence underpinning what we sell today; now let me turn to what comes next. So IM8 hydration is slated for the first quarter of '27; we said earlier that titration would launch in Q4 of this year. The reason we moved the timing is that Q4 is extremely hectic thanks to Black Friday and Christmas sales. We were after a quarter dedicated to just one product, and that's going to take place in Q1. What gets me excited is what all our athlete ambassadors have been telling us about the hydration product, which they've been using for many months already. They continue to return to it. They continue to request more; so I'm confident it will be an incredible product. I've also been taking it myself in the afternoon, and it has become a routine I look forward to; so hydration is the first of two launches next year. The second launch, Care Bears by IM8, is slated for Q2 of 2027. Regarding Care Bear, our approach was to secure an exclusive global partnership with Authentic Brand groups lasting ten years. Our starting point will be gummy multivitamins aimed at kids and grown-ups. Eventually, we intend to broaden the range into better-for-you confectionery as well as wholesome snacks and foods for children. This one has me personally enthusiastic, since it brings what we do into family life. Parents who grew up with Care Bears can share those characters with their own kids as part of a daily wellness routine; we will run the brand, recognize revenue and pay Authentic a royalty; and bear in mind, that royalty is not double counted by the royalties on the IM8 side. So within this partnership, Authentic is also going to turn into a strategic shareholder in Prenetics, which is a partner that has deep experience when it comes to building and entering brands. Andrew, could you play that short video we launched a few weeks back, just so everyone gets a sense of the kind of content we'll be able to do thanks to this partnership? Yes. To give you a sense of what's achievable — I mean, I was raised on Care Bears, and plenty of my friends were too — this will also help us get into retail stores, which is quite thrilling as we grow in that channel. Moving to the next slide, you can see our new products there. And beginning with — let me capture next year in a single picture, beginning with what's included in our guidance. As I mentioned before, we're reaffirming our $400 million guidance for '27; that reflects our two existing products that customers purchase today. It contains nothing from our hydration category or from Care Bears. Roughly 44% of that $156 million shown on this slide comes from existing customers and channels, while marketplace and B2B contribute approximately $19 million more.
That figure comes before we had brought on even one new customer in '27. So this is a projection and a forecast. And as you're able to see, two additional moves are planned past the launches, and none of that appears in the guidance either. As I mentioned, retail also isn't included in the guidance, and we're building care bears with a retail-first focus together with a DTC strategy. The second major opportunity, which likewise isn't in this forecast, is China, a supplements market worth roughly $50 billion; our plan is to launch in China by the end of '27, and both of these hinge on securing the right partners and meeting the right local regulatory requirements. Now, stepping back a bit and taking a look at just how early we are. In under 2 years, we went from 0 to a run rate of $284 million; that equals 0.4% of a $200 billion global opportunity in a category, and this category has no dominant leader; based on industry data, no company holds more than about 5% of it. If you consider that 1% of our core markets alone would exceed $1 billion a year in annual revenue, which is an illustration rather than guidance, but it's also the other half of the reason we are investing now. So putting it all together, next year, for the first time, we will have 3 engines running instead of 1. We'll have our core daily nutrition business, hydration, and Care Bears by IM8. Personally, I've never been more excited about what lies ahead of us. But I want you to judge us on what we deliver quarter-by-quarter. With that, Brian, let me hand it over to you to walk us through the financials, the cash position and the outlook.
Sure thing, Danny — and good morning, everyone; thanks for joining us. First off, I want to say how much I value the confidence Danny and the board have placed in me, and Steven, you've been a terrific partner through this whole transition — thank you. During my six months here, much of my focus has gone into building a lengthy and economical financing runway that can back IM8's record-breaking growth over the coming quarters and years. That effort has involved assisting in putting together the growth facility of as much as $1 billion with general catalysts, and also in gaining a thorough grasp of our customer costs, our returns, our cash conversion cycles, and the places where margins can grow. Today, my remarks will reflect that work as it continues. I’ll concentrate on the results, how we financed the quarter, and what is included in our outlook. Except where I say otherwise, please treat the financial figures I mention as Prenetics group continuing operations. Revenue for the third quarter was $64.1 million, representing a 37.9% increase sequentially and about 3.3x the prior quarter — Q3 of 2025. On the screen you can see that IM8 revenue hit $62.9 million, rising 39.8% quarter over quarter and roughly 3.7x compared with the third quarter a year earlier. Both figures came in slightly above the upper bound of the ranges we provided last quarter. IM8 now represents substantially all of the group revenue, which also explains why we moved to a single CFO structure. Those are the top line results. Now let's go through the full P&L. All right. So here is the entire quarter on 1 page, showing the strong progression of 2026. As you'll note, this has been a really strong story of expanding leverage across most areas of the P&L. We discussed revenue being up 38% sequentially, with gross margin of 64% in the quarter. In fact, it was a small step down. The cause was a onetime inventory charge of $1.3 million tied to older formulations; we reformulated the product, and those older formulations were written off during the quarter, which produced a slight step down; we expect the margin to continue at the 65% in to keep for and beyond. Operating costs, which are payments, people, R&D and everything else we control, fell from 25% of revenue in the first quarter to 16% now; so great leverage on this line that will continue; and this operating leverage is why contribution profit reached $30.6 million, or a 48% contribution margin; we publish contribution profit and contribution margin because it shows the profitability of the business before a single growth dollar is spent. Because allocating those dollars is a capital allocation decision, we make it intentionally and with historically very strong cohort returns as the benchmark. Beneath contribution lies the growth investment, which you can see there: $40 million for acquisition marketing, along with our royalty and ambassador cost lines, which have now fallen to 5% of revenue combined for the quarter. That produces an adjusted EBITDA loss of $12.7 million, equivalent to a negative 20% EBITDA margin. That is an improvement from negative 39% in the prior quarter. The entire adjusted EBITDA loss stems from growth investments, and we gained solid leverage across the P&L in almost every other line. From there, the bottom table takes you to the IFRS net loss of $25.4 million. Set against the $9 million we recorded in Q2, that figure stands. Within this loss you'll find a $7.2 million noncash fair value loss tied to our warrant liabilities, and that charge grows whenever our share price rises, which is what happened in Q3. You'll also observe that Q2 received a boost from a fair value gain along with a disposable gain during that quarter. Given all these items, the line that clearly warrants the closest look is the $40 million spent on acquisition marketing. Let's go to the following slide and take a look at what that spending delivered. Danny already touched on this, but cash was down for a second quarter in a row, and that's a good thing to see. On the customer side, we brought in 137,892 new customers, roughly 16% more than the previous quarter. Dynamic marketing spend came to $39.3 million for the quarter, about 10% above Q2, which works out to a customer acquisition cost of $285, compared with $301. When we last reported, we noted that July stood at $239. That month was exceptionally strong for the brand — it wasn't a level we were budgeting for, and we don't budget around it either. For the remainder of the quarter, if you run the numbers, that's $28 million in spend at a $310 CAC. As Danny mentioned, September set a new record for a cohort, with 52,696 new customers — a great month. New customer AOV was also unchanged from Q2 at 2.07%, so think about what all of this means. Starting in Q1, we increased ad spend on the IM8 brand from a bit above $18 million to $40 million in Q3, and CACs came down by 7%. That holds at any scale, and keep in mind we're adding tens of millions of dollars each quarter. Normally it works in the opposite direction, where tax tends to rise rather than fall when you spend that much more. What this demonstrates is how strong the brand is and how well our marketing engine is performing. This also demonstrates that even with the flexibility the General Catalyst facility provided for financing growth beginning this quarter, we're still being quite disciplined in how we allocate capital. So let's next examine the General Catalyst facility and its mechanics. The funds partnership offers a growth commitment of as much as $1 billion. Naturally, that $1 billion isn't capital sitting on our balance sheet. We draw against this $1 million over time, based on 70% of our acquisition spend every month. When a particular month's cohort arrives and has been funded, General Catalyst receives 70% of that cohort's gross profit each month as subscriptions renew, until the principal is recovered. Then, based on how quickly that principal comes back, they get a defined premium on top of it, and that premium is paid only after the principal has been repaid. What that premium amounts to is shown on the next slide. It hinges on how fast the payback happens. So on the right-hand side you can see the various payback-speed ranges. If we land in those ranges, the percentages are visible there. After a cohort’s principal plus premium has been paid, General Catalyst’s participation in that cohort is over. At that point, all profit from those cohorts belongs to us, and it had been prefunded in a strong cash-flow manner. This structure lets us fund the acquisition-investment portion with the future receipts each cohort is meant to produce. Also, as a reminder, this financing was nondilutive. The cost — the cost of this financing is really just the premium share we’re showing on the right side. That is its only cost.
Because what they get back — the return really hinges on those same two figures we run the business on: the cost of acquiring a customer and what each cohort gives back — discipline is naturally embedded in how growth gets funded. That way, our incentives line up with the facility. Moving to the next slide. This is the first quarter General Catalyst will appear on our financial statements, so I figured it would be helpful to show specifically in Q3 where to find them, so you can check for yourselves; on the P&L, the whole footprint sits in financing cost below EBITDA. Revenue, gross margin, acquisition marketing — none of that is affected at all by the General Catalyst facility. What shows up is simply $0.8 million of effective premium accrual in financing costs, and that sits below adjusted EBITDA. On the balance sheet, the $34.7 million is there — those are the borrowings, which include $31.6 million in net cash fundings we received, plus $2.3 million of true-up owed by General Catalyst at quarter end that was settled in October. That same balance sheet line also holds $0.8 million of accrued finance costs. On the cash flow statement, it comes through as cash from financing. On adjusted free cash flow — a non-IFRS measure — we take operating cash flow, which was negative $27.5 million for the quarter, net of CapEx, and CapEx came in at 0 for the quarter, then add the GC cash funding inflow of $31.6 million. That gives us positive $4.1 million in adjusted free cash flow for the quarter and lifts our ending cash balance. Moving to the balance sheet for a quick review: September ended with $111 million in cash and current financial assets, compared with $109.4 million at the close of Q2. That figure consists of $63.4 million in cash and cash equivalents plus $48 million in current financial assets. Stockpiles climbed to 21 — excuse me, to $20.1 million, compared with $14 million when Q2 closed. Beyond that, we independently increased deposits along with prepayments to suppliers at our manufacturers in preparation for the holiday period and the items slated for the coming year. As shown on the prior slide, the balance sheet holds $34.7 million in borrowings through the General Catalyst arrangement. Thus, during the initial quarter of availability, the partnership delivered exactly the way we had planned. We managed to grow the cash balance in a quarter when, one, we spent a record marketing investment to acquire the largest quarterly customer cohort we've ever had; and two, we'll significantly bolster our inventory reserves in preparation for a big Q4 and into next year, especially with some new product launches. Now let's move on to our outlook. We're reaffirming total revenue guidance for full year 2026 of $220 million to $230 million, which includes I&A revenue of $215 million to $222 million. If we subtract the 9 months we've already reported from those numbers, the fourth quarter comes out to roughly $73 million to $83 million for the group, and $73 million to $80 million for IM8. For the back half, we're looking at an adjusted EBITDA loss between $30 million and $35 million, versus the negative $8 million to $12 million range we gave in August. As Danny noted, after that $12.7 million in Q3, the range works out to a fourth quarter adjusted EBITDA loss of about $17 million to $22 million. In dollar terms that loss is bigger, but measured as a percentage of revenue it actually gets better, moving from 31% in the first half to 23% in the second half at the midpoint of our guidance. During the back half of the year, a larger portion falls in Q4—roughly 25% of revenue as an adjusted EBITDA loss, compared with a 20% adjusted EBITDA loss in this period. That reflects an intentional boost to customer acquisition spending we have slated for the fourth quarter. That stretch also tends to be a more costly one, and we're making this move from a strong position. We closed September with $111 million — pardon me, $111.5 million in cash and current financial assets, an increase from June, in a quarter of record spending. General Catalyst finance accounts for 70% of our acquisition spend. As a result, our balance sheet is ready for new products, clinicals and the brand. We are putting this money in as we head into the holiday quarter and get ready for the mix of products for next year's launches. The returns show that all of this is paying off. The ratio of lifetime value to acquisition cost that we steer the business toward is 3:1. As Danny mentioned, our earliest customers are already well beyond that, at 4.1x, in under 2 years; the next 91,000 customers sit at 2.7x, and they will clear the 3.0 mark by early 2027. As we mentioned, CAC has also come down for straight quarters. So for the same reason, we will keep investing in Q2 for as long as our returns hold. Even with operating cash flow in the red because of the general catalyst financing, we still anticipate adjusted free cash flow will be positive once more in Q4. In addition, we're reaffirming that IM8As will reach an annualized revenue run rate of at least $300 million by the end of the year, and our operational investment priority for Q4 is to meet demand while getting ready for the exciting product launches we mentioned earlier. For 2027, we're restating our revenue guidance for IM8 of $400 or more based on the current product catalog. That figure excludes any revenue from hydration, care bears, other products, retail or China, so all of those represent upside to the current guidance. Naturally, as Danny showed, none of that forecast is earned. Remaining focused on keeping customers, acquiring them efficiently, and executing all year is essential. And lastly, we're introducing a long-term financial framework for the very first time. People ask me about this frequently — how the business will look on margins once it matures. So I thought showing it would be genuinely helpful. Eventually, we're aiming for a gross margin of 70% to 75%; we're aiming for operating costs of 8% to 12%. Costs for brand royalties and ambassadors ought to decline to 3% to 5%. Acquisition marketing ought to fall within the 35% to 50% range, and that would bring the business to an adjusted EBITDA margin between 15% and 25% once it reaches maturity. Looking at how things progress in '26, you can tell we're making solid headway toward those figures, though plenty of work remains, and keep in mind none of this constitutes guidance, nor do we have a fixed timeline for any of it, but these are the targets you should expect us to keep pushing toward across every one of these lines. Gross margin especially. A new third-party manufacturer came on board during Q3.
Once they come online, we'll be adding more capacity along with lower production costs. So gross margin should improve in the early part of the period; we're not ready yet to state precisely what the gross margin guidance for Q1 will be, so look for some of that next quarter. Our operating costs don't go up each quarter. That, then, should let us really pick up more leverage. Royalty and ambassador costs work the same way. And acquisition marketing will, of course, decline over time as our subscriber base expands and more revenue comes from our existing base. Again, to be clear, those aren't long-term targets and aren't guidance for any particular period, but hold us to these metrics, since this is what I'm looking to drive us towards. Moving our finance leadership to the U.S. brings us closer to our largest market and primary capital market. Cindy Tab joined us in August as our VP, Financial Controller; she's an important part of our build-out, and you can expect us to keep adding experience to U.S. leadership in the coming quarters. Thank you to all of our Prenetics and IM8 teams for their tireless support, and thanks to all of you for joining us today. I'll hand it back to Danny now for closing remarks, and then we will open it up for questions.
Thank you, Brian. Before we start taking questions, I'd like to leave all of you with a handful of points. Revenue is on the rise, cash is on the rise, and the community of people who trust IM8 is expanding more quickly than at any point before. Extremely few businesses ever get a window like the one in front of us, and certainly not in a category as crowded as supplements. A brand that gets stronger each month, a partner financing 70% of what we spend on acquiring customers, and data that shows what every cohort returns. We're building for the long term, and the path ahead is very clear. New products, new sales channels, new marketing channels, and deeper international markets. We could be profitable tomorrow if we decided to be. At this moment, we're choosing growth. We also have a very detailed shareholder letter and an investor deck running to so many pages, and I'd suggest everyone take a look at those and review them; for now, thank you, everyone, our customers and our shareholders and everyone who joined us today. I'm happy to take questions from anyone.
Congratulations on yet another solid quarter. There are some good updates on both China and retail, and I'd like to dig into those two opportunities — could you walk us through what has to happen before you can launch in China and in retail, whether that means new investments, capabilities you need to build, or relationships you need to develop — help us understand the path toward entering China and then your plans for getting into retail too?
Sure. I'll begin with retail since that's probably less complicated than China. On the retail side, what's interesting is that with our current 2 product skills, honestly every major retailer in the U.S. has asked us to get into retail. We haven't done it yet because we didn't feel it was the right product at — but with care bears and hydration products, since these 2 products cost less than our current skills, we believe this is far better aimed at a retail opportunity; so we're currently talking with all the big box retailers; and we do expect to be on retail shelves by the end. Of course, we've had no retail experience before, but we had no DTC experience either and we managed to accomplish amazing things there, right? So we do believe our capabilities transfer very well to retail. We will certainly need to bring on a few new people in the U.S. to manage those retail big-box relationships. But we're quite confident we can do it. On China, again, China is a much, much bigger market. So we're working with a few different potential partners to enter China, with people who know the market and know the industry, again, because in China the way it works is that no 1 actually transacts on your own website. Everything goes through third-party Tmall, JD, Yang, Red bulk, et cetera. But again, given my resources and my network there, I'm very confident we'll be able to find a very trustworthy partner and be live in China by the end.
That's genuinely useful information, and I'm grateful for it. One final item from my side: could you walk through some of the forces shaping what we spend to acquire customers? It's clearly encouraging to see the step-downs — a drop in July, followed by increases in August and September. What precisely caused those movements? And how should we view those forces looking ahead?
Right. Looking forward, I'd say these forces will always fluctuate month to month and quarter to quarter, and around the renewal cycle. That's exactly why, going forward, it's far more meaningful to look at our CAC on a quarterly basis, correct? The nice part about the CAC, I'd say, is that for a minimum of two quarters back to back, it went down. Then when you compare Q1 with Q3, we spent over twice as much yet the CAC came in lower. That strikes us as a pretty meaningful number, since usually when your spending climbs that much, the CAC for just about every reason keeps rising — but we managed to bring it down. That makes us feel even better about putting more money into growth. To put it in terms of growth spending, the fact is that each new customer we bring in today sets us up to do even better once Hydration and Care bear launch, and we gain far more brand visibility when retail arrives. So in a lot of ways, given the strength of the returns we're seeing, we want to be considerably more aggressive with this investment opportunity right now.
And how should we think about this moving forward? Do you expect it to stay in that broad — let's say roughly the 300 level? Is that the right frame, or just for the next couple of quarters, since obviously some of this can move around — but is this the range you keep seeing?
Yes, that range sounds right to me. I'd put it within a 10% to 15% band, which lands around that 100 mark, correct? Because again, it depends on seasonality. So right now in Q4, everyone will be bidding up against acquisition, bidding in auctions, and so on. Then in Q1, of course, there are going to be opportunities from a decrease when we run certain off-line events. So taking all of that together, I'd say roughly 300, plus or minus 10% to 15%.
That's really useful. Congratulations on yet another solid quarter.
Also bear in mind on the CAC side, something quite interesting there is that if you look simply at CAC, which has been rising across roughly the past 3 to 4, 5 quarters, an important piece of that is our CAC went up, yet our average order value climbed very substantially as well, correct? So our average order value today sits well above $200, which, again, for a new customer arriving is fairly substantial.
I just wanted to ask — I don't believe you covered the marketing channel strategy for what comes next. Could you bring us up to date on your plans in that area?
So we've really — so regarding the marketing strategy, I think I brought this up back in Q2, correct? So we're mainly focused on matter, right? So over the last quarter — the last 2 quarters, we've really been branching out from Meta. So we launched TikTok, we launched a Loving. We launched Snapchat. We launched next month, we're going to be running connected TV, linear TV, right? So we're growing into quite a few of these different channels, which in the end will broaden our revenue base and make us less reliant on meta, because when all is said and done, if something went wrong with meta, then that wouldn't be a good sign, right? So with this diversification already in place, and we're seeing strong signals across all these other channels, which is also a very positive signal for the business. since we're able to reach new audiences across multiple channels.
So at this stage, Danny, are you sort of still testing things with those other channels? And would you be expecting overall performance to just improve with a more diversified mix?
I'd say a number of these are still being tested, though naturally, several of them have already moved past the testing stage, but that's where I really think a major reason you've seen our CAC drop essentially, from Q1 onward, is all these channels being diversified, right? Had we stayed with Meta only, Alcatel would have gone very, very high. But thanks to that diversification, we're becoming far more efficient on the marketing side of things, right? And we do believe that into retail, that will be yet another channel where I think we'll achieve even greater efficiency.
One last thing I'd like to ask. Since the earliest cohorts have performed so obviously well, is there any reason not to anticipate that later cohorts — particularly given the higher acquisition costs and so forth — will exceed that 3:1, exactly as you're seeing with the early ones?
Yeah. We see every reason to expect the same pattern our earliest cohorts have shown, correct? Looking at those earliest cohorts, they've already returned 4.1%, and that's in under 2 years. The following 90,000 people — that's Q2 and Q3 — are already sitting at 2.7, and by early '27 they'll be nearing 3x. So we have no shortage of reasons to expect that group to land in a comparable range too. And remember, every one of those earliest cohorts had just 2 products, correct? Looking ahead, we'll be launching additional products, and during the first half of '27 we're adding Hydration, along with gummies for kids and adults, right? So you really ought to anticipate that this trend keeps going even when measured against our most recent cohorts.
During the quarter, I suppose I mainly wanted to ask about the marketing for the new products you're launching, especially as they head into retail—things like the Care Bears. I'm just curious what the plans are on marketing: will it be a similar approach to the one for your current core products, or will you change it up given that some of these will be sold in retail?
Yes. Of course, there will be a difference when it comes to offline marketing, right? So we're going to run plenty of offline activations alongside the big box retailers, and there will be a lot of end cards available at the offline retailers; we're also going to drive a lot of online-to-offline traffic, which we haven't done before; but I think the great thing is that, again, with Care Bears and hydration products, these are already, I'd say, at least within the wellness supplement category, 2 of the most sought-after products that people search for in retail. Right? And then so—and then again, going back to all the brand investment we're making now, when we are in retail, people will recognize IM8. The last thing you want—and a lot of the reason, again, I study a lot of this stuff when it comes to go-to-market strategy—is when a brand gets into retail and there's no demand, right? And you need to be able to drive that demand because no 1 recognizes that brand. So I think a lot of the brand equity, the brand investments we're making today, are going to pay off significantly once we get into the retail channel.
All right, great. And then perhaps just one follow-up question. I was wondering, sort of, about the...
And one more item I can mention as well, Susan, is that this is going to be a major advantage for us too, correct? And specifically for careers, it's that Care Bear's 45th anniversary falls next year, so on their own, care bears are going to be doing plenty of offline physical activations and online ones too. So that will naturally benefit us when it comes to brand recognition, or people getting a better understanding of the brand.
Turning to IM8, how are you viewing the distribution opportunity from here? Could there be room for retail spending — I'd welcome any color on that. And my second question: as your base of brand ambassadors keeps expanding, what's the plan for leveraging that down the road? Does your approach change as you look to next year?
Yes. As I said, retail is definitely part of our plans. I think even investors see this as making the business far more investable, since we won't be purely a direct-to-consumer brand. Shoppers will be able to find us on shelves. So as mentioned, by '27 we'll have at least a hydration in Carvers brand in retail — so 10% on retail. On ambassador relationships, we evaluate a great many of them individually, case by case. And as I said earlier, each of these major ambassadors who joins actually found us, and usually that happens through a recommendation from their nutritionist, their doctor, or a friend, and they're taking a product they enjoy being part of. They use the product every day and they seek us out. So I believe those are the finest kinds of partnerships. These ambassadors begin as users first, then they come in wanting to work with us. A lot of people ask me who we'll sign next, and the truth is I don't know who will reach out to us next. Right? So once they do reach out, we check whether it's a fit for the brand. Of course, it also has to work on the commercial side. But since these individuals love IM8 so much, we can always secure really strong partnerships from them.
And just one final thing — clearly, New Year matters a lot for wellness items, and you're operating at a bigger scale now. Are you approaching marketing any differently for the New Year period?
Yeah. I'd point to Q4 and Q1, right? Q4 and Q1 carry the heaviest seasonality for the business. Partly from Q1, again, new year, new yield — so we'll be rolling out hydration products in Q1. That's going to be a change, alongside our existing essentials and longevity products; and one big thing you'll keep seeing from us is that we keep running plenty of off-line activation events, and that will continue especially at the Hydration launch, because naturally there will be many multiple flavors. Then our offline events, again, going back 22 months, and that's something that truly sets us apart from everyone else — people can see the product, they can talk to our Scientific Advisory Board, they can talk to our ambassadors. I meet with them. So we've now done 200-plus events over the last 22 months. I think that really gives the product a face as well. And then with hydration, we're going to hold more of these kinds of activation events around the world.
All right, thanks, and good morning. We've discussed CAC quite a bit during this call, but I really want to stay on it — you lifted the second half loss because marketing spend went up. You lifted it, though, since you plainly see the opportunity out there and you want to keep pushing hard. I understand that. But how come we didn't raise revenue guidance either for Q4 or for next year?
Brian, would you like to handle that one?
Yeah, there's quite a broad range in that number. Part of it is that in Q4 we loaded the funnel with lots of customers who became aware of us thanks to the Q3 push, and a good number of those customers are now in our mix and will hopefully convert as Black Friday arrives. So instead of lifting the revenue guidance, we chose to leave that rather wide range in place and hope it proves adequate; we also don't want to set the mark so high that we're uncertain about how it would look. So we're comfortable with the revenue guide as it stands, since it's already a pretty wide range.
Yes, and one more thing I would add is that, when you consider where we stand right now, the brand is 22 months old, correct? We are only in our second year, and we have already reached — we are going to reach more than $220 million in full year revenue; and in the next year, our target is $400 million in our third year. At least within the supplement category, no company has ever accomplished that at such speed and with such growth. So we believe we are already at a very good point, and we want to keep some upside available there, right? Again, hydration, in our view, is a big category. Carver is a big category, but we are so focused on growing the business today through new product development and growing the existing business; we simply felt that at 400. That gives investors a lot of upside opportunities for us to capture on that.
Yes, absolutely. Your shareholder letter also referenced the plan tied to 2027 adding up to over $400 million. So I completely understand that. I do want to return to our earlier point — and you have brought on some genuinely strong partners. I'm really excited about what's possible in the running community, especially with the new hydration launch. And I realize you can't — the idea is that a partner adopts it first and afterward approaches you. But you also gain somewhat more focus on particular channels. What other areas are you specifically going after? For instance, any specific sports where you'd really like to land a partner, or certain celebrity niches you have your eye on?
To be fair, I think we've built — if you look at the athletes and individuals on our roster, right, it's already fairly diversified; and we want to do more with the individuals we already have. I think there's one thing we're seeking. I mean, I wouldn't phrase it as seeking it, but if there were 1 niche where we haven't. I think it comes down to when we consider China. So we're looking at a few different individuals who could truly help us push the envelope in China for when we launch there, but apart from that, again, every day has been insanely busy, right? And so I think we're very excited and pleased with the roster we have. So I can't say there's some specific new area we're pursuing from an ambassador partnership standpoint. And as you mentioned, Alex, I mean, the running club piece represents a huge opportunity for hydration, right? I think across the world, you see running clubs forming whether it's 50 people, 100 people. I mean Diplo's running club has reached 10,000 people now. He only began it about a year ago. So that's a prime opportunity for promoting our hydration product when it launches in Q1.
My first question concerns the general catalyst financing. Since that facility has now been in place for a whole quarter, how should we view the interplay between fresh draws and repayments as it matures? And then, when do you figure the business can begin producing positive operating cash flow on its own, without depending on general catalyst funding?
Sure. So in the quarter, repayments came to $7 million while draws totaled $31 million, and at quarter end they still owed us a few million. For a significant period, the amount we draw down every single month is going to be greater than the total repayments, and that will hold true for an extended stretch. So when you project the business forward and build your models, it's roughly—I'd say around 18 months into the arrangement—that I begin to see incoming cash approximately equal to the cash going back to them. At that stage, it would become cash neutral. That said, being cash neutral is a very different situation from us financing our own acquisition dollars at that point, and it depends on how big the business is by then and what our monthly spend looks like. That would all come out of our own cash, while a misworld that's cash neutral in that kind of setting is still quite robust from a cash flow perspective. Then you asked about when we might potentially flip to positive operating cash flow — that's comparable to when adjusted EBITDA might potentially turn positive. And we haven't wanted to get too far ahead of ourselves by trying to guide on exactly when that will occur. I mean, depending on how you model the business, it gets pretty hard to outrun the math of how large the existing customer base is and how much contribution profit and dollars you're getting from your existing customer base? At present, we have 160,000 subscribers, and that figure keeps rising. As a result, your recurring revenue from existing customers will keep growing so substantially that, unless we keep investing large sums to drive sequential growth each period compared with the one before, it eventually becomes too difficult to outpace the arithmetic, no matter how much we may wish to invest, when we hold ourselves to that 3:1 return — you'll arrive at a point where we cross the chasm to profitability. And that will — again, we don't want to attach any specific timelines to it. That moment isn't especially distant, in my view. Everything hinges on how much we can continue investing at our three-to-one return around the roughly 300 cap; so far we've managed to increase our spending at that level again and again. If we keep handling it that way as time goes on, the gap will just get wider still—but should we allow growth to decelerate, spending would decelerate as well, and that point would come around quite fast. In other words, we could potentially reach profitability next quarter by cutting back on spending, yet that wouldn't be the best outcome for our shareholders over the long run.
All right, understood. Then second, perhaps for Danny, could you give us a bit of commentary on what you believe is letting the IM8 brand in particular achieve customer retention that's above average when it comes to supplements?
Honestly, on that point it's pretty straightforward, right, because the product does what it's supposed to. And I think we've — again, right from day 1 — we had a great launch, that advisory board, third-party testing. NSF certification. And so when you consume it over an extended stretch, you build the habit, it delivers, and you'll stick with it. So I think that's the primary reason retention has been so strong, right? And I think we've also really concentrated not only on how well it functions. But also on taste, at the same time: when we first launched, we had 1 flavor; we've since brought in 2 new flavors. In Q1, we're going to roll out another flavor. So I think these fresh updates to both the formulation and the taste keep pleasing our current customer base again and again.
Great. So Danny and Brian, I have two questions about artificial intelligence, and I'll direct them to both of you together. Could you bring us up to date on how you're able to leverage artificial intelligence to grow the business without adding significant head count? And then second, regarding agentic commerce, Meta's had tremendous engagement based on the number of downloads for us, how are you positioning yourselves to take advantage of that opportunity?
Great question. Tom, good to connect. So I think on the first part, in terms of how we're using AI, I think, again, if you look at, at least in direct-to-consumer space, right? For anyone operating in this sector, content is really the crucial element. You have to possess a large volume of content spanning numerous channels; and much of what we rely on essentially involves leveraging AI to generate a great deal of material — whether or not it's static video — alongside genuine short-form videos, and essentially employing AI to slice them into far more numerous distinct pieces of content. So, to give one obvious illustration — I believe I mentioned this before — when you check our Meta public ads library, at any moment we'll have somewhere between 3,000, 4,000, or 5,000 advertisements live simultaneously. So next, we’ll use AI to spot the winning ads really quickly. Once we find those winners, I’ll run those same ads across AppLovin, X, Snap, and TikTok. On top of that, every week we’re testing a lot of fresh content — 500, 600, 700 pieces weekly. Honestly, if you don’t know what you’re doing, that’s extremely, extremely hard. That’s the reason very few brands are able to scale at the levels we do. Right? So I think that gives you a pretty clear example. That's the reason, again, even at this moment, when you consider the size of our whole team, we're at roughly 70 to 75 people. And when you factor in what we expect to bring in over the entire year, which will comfortably exceed $200 million, that works out to around $3 million in revenue for each employee annually. Looking ahead to next year, with $400 million plus on the horizon, we'll likely bring on some additional people, so we'd land at around 100 employees against $400 million. That comes to approximately $4 million per employee per year, and we consider those to be excellent metrics, correct? On the agent commerce side, yes, that's a good question. At the moment, we're actually running tests that include ads inside Taco, and they've already opened that up. My belief is that it's still early, though things are going to progress very, very quickly, correct? So in my view, over the next 2 to 6 months—perhaps a shorter window still—a large number of people are going to depend on their AI when making purchases. Frankly, in my own situation too, I'm using mills in stake to purchase items via the AI. So it's hard for me to think that won't turn into the norm across the coming 3, 6, 12 months. And once more, considering how much effort we're ready in this—or rather what we're doing with AI, we're confident that we can lead the pack in that area.
That was quite a strong quarter. I'd like to return to the retail entry point. I'm curious: do you have agreements signed with retail partners at this stage? And could you shed some light on that — maybe tell us which ones? Then how would the ramp unfold? When do you expect — do you think you'll fold this — the retail launch into guidance?
Yes; so regarding the retail side, to be transparent, no agreements are in place yet. All the big retail partners have been pressing us hard, I'd say, for the past year; so this is something I'm hands-on with, collaborating closely with that large-format retailer; and once more, we're not able to say which one, but it's — well, it's a major player in American retail, correct? And we anticipate launch before '27 wraps up. And I genuinely think at this point it remains far too soon to offer any kind of guidance regarding what that will be. Even so, speaking for our team, we feel quite positive about what this large-format retailer could bring, especially considering how broad our lineup and the specific products we already have are. And naturally, as soon as we secure shelf space—which I expect will happen shortly—we should be in a position to share projections on the size of that opportunity.
All right, understood. Then, regarding the ambassador network, I suppose, are there any particular plans you have around things like activations with the ambassadors, and how do you turn that visibility into subscriptions? Could you attempt to quantify any of the benefit from the investors?
Yes. Absolutely, right? So I believe each and every one of our ambassadors has more than paid back far more than we've given them. So quantifying it is actually pretty easy for us. It isn't only from the — do we hear the off-line activations is more brand activity events. But take, for instance, when we partner with Jan, arena sublink et cetera, content and digital profiling is one of the key things for us. So we're able to utilize partnership and white listing ads. For instance, Giannis, he has 20 million followers on Instagram. So we can market from Giannis' handle Aryna's handle to their followers, right? So the ROI can be measured directly. We have on these ambassadors; and for every single one, it's been positive because we're putting paid ads behind it. And because these are individuals that are well known, if you have an ambassador, which is well known, yes, these will perform 20% to 30% better than just a normal individual promoting that same product; so it more than pays for itself.
A couple of questions for you. First, I believe I caught something in the prepared remarks about a change in manufacturing partners. Did I get that right? And could you share the reasoning behind it — perhaps it ties to the gummies or to pricing? I'm not certain, so any specifics would be useful.
Yes. So regarding the manufacturing partner — it's actually a new manufacturer that we're bringing in for the hydration product, and it also adds capacity for our existing products. And naturally, for the gummies, that will be a separate manufacturer too.
But when it comes to the core product, are any changes on the way?
Regarding the core product, we're bringing on more capacity, simply because at our present scale we can't rely on just 1 manufacturer. That's why we're also bringing in a second manufacturer, so we're covered if something happens, correct?
All right. All right. Got it. Then my second question. Going back to the guidance you revised, the EBITDA change. Would it be fair to say that, like — I suppose I'm simply attempting to dig into the trends you've observed regarding CAC in October and November. And I'm curious whether there's something that perhaps wasn't sort of fully appreciated in the guidance you gave previously. Could it be the election, or am I just trying to understand sort of how CAC has shifted relative to what you expected earlier?
Well, on the core it hasn't shifted much — I mean, again, when you look quarter to quarter, right? So I think NTA came in at roughly about $285 in Q3. And then, again, we believe it will move around within 10% to 15% of that range, roughly about $300, right? So we feel that if we can hold our spend, hold our CAC where it is now, we're in a good spot. And the reason we're in a good spot is that we know at this CAC level we'll be able to get payback in approximately 6 months, and we'll also be able to hit that 3:1 ratio across a 36-month period of time.
All right. Perhaps I could squeeze in one more quick question. About the updated gross margin target — that longer-term goal of 70% to 75% — what kind of visibility do you have into that? And, like, are these manufacturing changes plus the new products and all of that a big part of — it's just — that's a big jump. So I'm trying to get a sense of your confidence.
Yes, it breaks into 2 parts. One sits on the manufacturing side, and the other piece sits on the fulfillment side; in both of those areas, I believe we've spotted some fairly low-hanging fruit, so that as we gain more economies of scale, we'll be able to secure better pricing in some of those areas. And so I'd say we haven't yet figured out how to reach the upper range of that target. It's quite clear to me how we'll move towards the bottom part of that range, with some work still to be done for sure, but fairly straightforward to get there within 4 to 6 quarters, I'd say. Again, that's not specific guidance, but like I'd expect us to approach the lower range of that 70% number toward the end of next year at some point; and then toward 75% as the business keeps growing and as we bring on additional capacity, you get some, again, more economies of scale; and I mean both parts of it, again, manufacturing and logistics. I think we'd be shooting for the upper range eventually, but the lower end is clearer in sight right now.
Great, thanks for all those updates. My first question is really about price elasticity and what kind of competitive dynamics you're seeing. You've clearly taken significant share from the top players. We also saw that 87% of new IM8 customers had no observed purchase from AD1 green or Thorn before their first IM8 order. So how have the pricing competitive dynamics been out there? And obviously, you've got a premium price on yours given the superior product, but should we expect continued pricing stability?
Yes. I mean, we haven't seen much price issues for us. To put it another way, our pricing has stayed the same since launch — well, actually, we did raise prices slightly — but we've encountered no problems with price elasticity or with demand, which the ongoing quarter-over-quarter growth makes clear.
Understood; and perhaps focusing just on the clinical trials for a moment. Could you expand a bit on how this might be opening up new segments of the population. Clearly, consumers are becoming far more informed and awareness is definitely growing. Do you expect the results to bring in a new cohort of consumers, or perhaps encourage clinicians to recommend the product more often? I'm just a bit curious about how you'll take advantage of that data.
Yes. So I think ultimately, again, we're probably 1 of the only supplement brands that actually launched our clinical trial before we launched the brand and the product, right? And so again, all of this gives us much more credibility and trust with that consumer. So of course, we'll be able to leverage that when it comes to marketing — a lot of marketing — and also, as you mentioned, clinicians will be able to prescribe it much more. So very, very positive and hopeful about these trials that are going to be releasing in the first half of 2017.
Thanks, and I appreciate you taking our questions. I'd like to begin with repeat orders; they looked really strong at 59% of customer billings in this quarter; and I'm wondering, as that proportion rises, how fast does acquisition marketing fall toward your 35% to 50% range? And what does that imply for when profitability arrives?
Yeah. So seeing 59% is good. That said, if we're able to keep investing at the 3:1, we would prefer to put more and more money into new customers; so there's a conundrum there, because when we put more into customer acquisition, the percent of new revenue is higher, yet that's a wonderful signal for what's ahead given the returns we get; and so I'd say again that profitability isn't really the objective. With the math, it's inevitable that eventually it just gets too difficult to outrun, as I said a little while ago. So — putting a time line on it is hard because we've been — we've gone beyond what I would have figured we could spend up to a cap that keeps declining. Should that carry on, then naturally we'll keep doing it, and at that point you push profitability out — if we begin to slow the spend, that pulls profitability forward into the nearer term. But yeah, saying precisely when that happens is too tricky, since we've been exceeding what I'd have thought we could spend. And so — and again, with new products and everything, we don't know how those will affect CAC. We don't know how it will affect overall LTVs and LTRs. And so we need to get these products launched before we can kind of model the future more precisely around a profitability target; but my expectation is that marketing will keep coming down as a percentage of sales, which you already saw from Q2 to Q3. I'd expect that to trend mostly downward, like there could be a few blips here and there, but mostly it will keep trending down to that range we provided for the longer term.
All right, that's useful background. And on the subject of new products, I understand Hydration is launching with roughly 160,000 active subscriptions. That's a large figure, so I'm wondering what attach rate you'd view as a success in year 1, assuming you have a target? And also, how might margins stack up against the core products? I'd say hydration and gummies were the 2 categories that came up when we surveyed our existing customers — they asked about them and wanted us to offer them.
So yes, I'd expect at least 15% to 20% of our current subscriber base to take this up. And I think it's also not just our existing customer base, right? The reality is that electrolyte hydration is a massive category. I would — it potentially is even larger than our current supplements or daily nutrition category, right? So I think we'll also bring a lot of new people in the door whom we can then cross-sell and upsell our current Essentials and Longevity product to.
Then, from a margin perspective, just to address those margins: from a product cost standpoint, the margin profile is going to be very comparable to what our existing business margin is, that's certain. On the logistics side, it hinges on whether we can move customers into a multi-month purchase or a larger basket and get them to attach either our existing products or an essentials bundle, or perhaps a 3-month supply of hydration, since that would let margins stay quite consistent with where we stand now. Should we see AOV beginning to fall because customers are choosing more of the 1-month supply of hydration, which comes in at a lower price point at checkout compared with our present assortment, you could see some slight margin pressure purely on the fulfillment side; shipping a product to a consumer costs us roughly the same whether they spend $50 or they spend $100; so a bit of pressure may show up depending on what AOV looks like — but on the D2C channel we will certainly be working to get customers into a multipack, and that would ease that pressure. What's completely — and then retail is the other unknown piece there as well. As you'd expect, the retail channel has a different margin profile, with substantially lower fulfillment cost and substantially lower cost on the actual ad dollar dedicated to retail. So as I model it out, I believe the margin across the total new products will be essentially unchanged against the current level. There will be some pluses and some minuses in there. But on the whole, I wouldn't anticipate much pressure on it.
That's really useful. Now one final question from me. I realize we've already discussed retail quite a bit, but that 2027 bridge also has roughly $19 million coming from marketplace and B2B, and I know that's only around 5% of revenue, but I'd like to hear a bit more about what the B2B opportunity looks like and, in your view, how quickly it might grow?
Yeah. So where the marketplace side is concerned, it's similar to Amazon, B2B, and actually we have plenty of other businesses contacting us as part of, say, their wellness efforts, correct? So once again, it remains a modest portion of our business overall. If you look at next year, our forecast is $400 million, right? So I think the emphasis will stay — and then retail, and then B2B and marketplace, those are more like haul opportunities that will pick up.
Thanks a lot, everybody, for joining us today. I hope it was quite insightful. As I said, there's a very detailed shareholder letter and investor deck. Yes, we just put that online. Yeah, again, to sum things up, this quarter marks another record quarter. We're moving into 2027 with a lot of strength. Revenues are rising, the cash position is rising. Our cohorts are expanding with new products; so at least from a business standpoint, it's very clear to us that we're building stronger momentum quarter over quarter and month over month. Yeah, so we couldn't be more excited about where the business is going. So thanks, everyone, for joining in, and we look forward to standing with very wanting the next quarter. Thank you.
Thanks, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Prenetics Global Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Prenetics Global Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.